Inventor · disambiguated record
Yupo Ma
Also filed as: MA YUPO
9 granted patents·25 pending applications·48 citations·filing 2001–2024
86Inventor score
Files withICELL GENE THERAPEUTICS LLC11ICELL GENE THERAPEUTICS INC6MA YUPO5iCell Gene Therapeuticics LLC4NEVADA CANCER INST3
Top patents by PatentIndex Score
34 records- 0192US10273280B2Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereofICELL GENE THERAPEUTICS LLC·Filed 2016·Granted Apr 30, 2019·18 cites·20 claims
- 0290US11820819B2Chimeric antigen receptors (CARs), compositions and methods thereofICELL GENE THERAPEUTICS LLC·Filed 2017·Granted Nov 21, 2023·5 cites·5 claims
- 0389US11655452B2Chimeric antigen receptors (CARs), compositions and methods of use thereofICELL GENE THERAPEUTICS LLC·Filed 2016·Granted May 23, 2023·6 cites·4 claims
- 0489US11173179B2Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereofICELL GENE THERAPEUTICS LLC·Filed 2018·Granted Nov 16, 2021·6 cites·1 claims
- 0587US11905528B2Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereofICELL GENE THERAPEUTICS LLC·Filed 2018·Granted Feb 20, 2024·3 cites·7 claims
- 0682US12275787B2Chimeric antigen receptors (CARs), compositions and methods thereofICELL GENE THERAPEUTICS LLC·Filed 2018·Granted Apr 15, 2025·2 cites·2 claims
- 0779US2024141041A1CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOFICELL GENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0878US7790407B2Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)NEVADA CANCER INST·Filed 2006·Granted Sep 7, 2010·6 cites·5 claims
- 0975US2023340113A1CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOFICELL GENE THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 1073US2024124547A1CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOFiCell Gene Therapeuticics LLC·Filed 2023·Application pending·0 cites
- 1172US9309496B2Method for expansion of stem cells and the use of such cellsMA YUPO·Filed 2011·Granted Apr 12, 2016·2 cites·15 claims
- 1272US2025002550A1Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereofICELL GENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1364US2024059754A1Chimeric antigen receptors and enhancement of anti-tumor activityiCell Gene Therapeutjics LLC·Filed 2022·Application pending·0 cites
- 1464US2024350632A1Engineered immune cells for treating disorders, compositions and methods thereofICELL GENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1561US2020283534A1CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOFiCell Gene Therapeuticics LLC·Filed 2016·Application pending·0 cites
- 1660US2023277622A1CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS THEREOFICELL GENE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1760US2023302051A1CHIMERIC ANTIGEN RECEPTORS (CARs), TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOFICELL GENE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1858US2022348633A1COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOFICELL GENE THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 1955US2022241327A1Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use ThereofICELL GENE THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 2055US2019345217A1CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOFiCell Gene Therapeuticics LLC·Filed 2019·Application pending·0 cites
- 2153US8609414B2Isolation and growth of stem cells from hemangiomasMA YUPO·Filed 2011·Granted Dec 17, 2013·0 cites·2 claims
- 2253US2024261401A1Engineered immune cells, compositions and methods thereofICELL GENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2353US2008299077A1Isolation and growth of stem cells from hemangiomasNEVADA CANCER INST·Filed 2008·Application pending·0 cites
- 2452US2021338729A1CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOFICELL GENE THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 2549US2018371052A1Chimeric antigen receptors and enhancement of anti-tumor activityICELL GENE THERAPEUTICS LLC·Filed 2016·Application pending·0 cites
- 2648US2009191171A1Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous RecombinationMA YUPO·Filed 2009·Application pending·0 cites
- 2745US2019135894A1COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOFiCell Gene Therapeuticics LLC·Filed 2018·Application pending·0 cites
- 2841US2008241110A1Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)NEVADA CANCER INST·Filed 2007·Application pending·0 cites
- 2939US2014271584A1Methods and Compositions for Direct Reprogramming of Somatic Cells to Stem Cells, and Uses of these CellsUNIV NEW YORK STATE RES FOUND·Filed 2014·Application pending·0 cites
- 3039US2012030780A1Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)MA YUPO·Filed 2010·Application pending·0 cites
- 3138US2015250824A1Methods and compositions for expansion of stem cells and other cellsUNIV NEW YORK STATE RES FOUND·Filed 2015·Application pending·0 cites
- 3237US2002156039A1Diagnosing and treating cancer cells using Sal2Filed 2001·Application pending·0 cites
- 3337US2015342999A1Methods and compositions for treating diabetes with ips derived pancreatic beta-like cellsMA YUPO·Filed 2011·Application pending·0 cites
- 3436US2002147996A1Diagnosing and treating cancer cells using Sal2Filed 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yupo Ma files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →